Research Reference
Sermorelin
Synthetic GHRH analog used for growth hormone stimulation
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Sermorelin is a synthetic GHRH analog historically used for growth hormone stimulation and diagnostic evaluation; it is no longer marketed as a drug in the US.
Dosing Reference
Reconstitution
Add 5 mL bacteriostatic water to the 5 mg vial. Resulting concentration: 1 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 0.3 mg | 30 units | 0.3 mL | SubQ, once daily (bedtime)Common adult protocol |
| 0.5 mg | 50 units | 0.5 mL | SubQ, once daily (bedtime)Common adult protocol |
| 1 mg | 100 units | 1 mL | SubQ, once daily (bedtime)Higher adult protocol |
| 0.03 mg | 3 units | 0.03 mL | SubQ, once daily (pediatric)Pediatric GHD dose (mcg/kg) |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
Sermorelin (Geref, discontinued in the US as a branded drug) is a synthetic fragment (1-29) of growth hormone-releasing hormone (GHRH). Compounded research-peptide forms are sold in 5 mg or 9 mg vials. Compounded forms are not FDA-approved.
For a 5 mg vial reconstituted with 5 mL, the concentration is 1 mg/mL; a 0.5 mg dose draws to 50 units (0.5 mL) on a U-100 syringe. For a 9 mg vial reconstituted with 9 mL, the concentration is 1 mg/mL; a 0.5 mg dose draws to 50 units (0.5 mL). Gently swirl — do not shake — and store refrigerated.
Cycling Protocol
Compounded sermorelin protocols commonly describe once-daily bedtime injection for 3–6 months, sometimes cycled with on/off periods. The original FDA-approved pediatric protocol used once-daily dosing adjusted by weight. No standardized adult cycle is established; compounded forms are not FDA-approved.
Routes of Administration
Subcutaneous injection (most common): Once daily at bedtime into the abdomen, to mimic natural nocturnal GH release.
No oral, intranasal, or intravenous route is established. Sermorelin is not orally bioavailable as a peptide. Compounded forms are not FDA-approved.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | GHRH + GHRP | Sermorelin + GHRP-2/GHRP-6/Ipamorelin | Combined GH secretagogue pulse (community) | | Recovery Stack | Sermorelin + BPC-157 | GH support + tissue repair (community) |
Stacking combinations are community extrapolation. Sermorelin (compounded) is not FDA-approved.
Side Effects & Safety
- Injection-site reactions — redness, itching, pain (most common)
- Flushing, warmth — common transient effect
- Headache, dizziness — occasionally reported
- Nausea — occasionally reported
- Hyperactivity / restlessness — rare, mostly pediatric
The original branded sermorelin (Geref) was FDA-approved for pediatric GHD but discontinued in the US. Compounded research-peptide forms are not FDA-approved.
Research Basis
Sermorelin is a synthetic 29-amino-acid fragment of growth hormone-releasing hormone (GHRH), the shortest sequence retaining full biological activity.
Mechanism: Binds GHRH receptors in the pituitary to stimulate pulsatile, physiologic endogenous growth hormone release (and downstream IGF-1), preserving feedback regulation.
Clinical evidence: Originally FDA-approved (Geref) for diagnosis and treatment of pediatric growth hormone deficiency; the branded product was discontinued in the US. Compounded forms are prescribed off-label for adult GH support; not FDA-approved for that use.
Compounded forms are not FDA-approved. The original branded product is discontinued in the US.